November 21st 2024
Coverage from the IVBM Regional event in Denver, Colorado.
November 18th 2024
November 15th 2024
Dr Rachel Dalthorp: Zuranolone Improves Access to Postpartum Depression Treatment
June 19th 2024"As a health care provider and as a psychiatrist, it's something that I think about first—instead of step therapy, when I have a patient with postpartum depression, this is what they need to be on," Rachel Dalthorp, MD, explains.
Watch
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma
June 18th 2024The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Read More
Link Between Skin Cancer and Immunosuppressants Needs Further Research
June 13th 2024At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.
Read More
Gray Matter Atrophy in MS a Strong Indicator of Progression, Study Suggests
June 13th 2024A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive disease.
Read More
Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma
June 12th 2024Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid carcinoma.
Read More
CMS Innovation Center's Latest Moves: Embedding Equity Into Value-Based Care
June 12th 2024During the CMS Health Equity Conference, health care leaders shared groundbreaking strategies to integrate health equity into value-based care models, aiming to enhance patient outcomes and reduce costs.
Read More
Dr Amit Singal on the Improving Outlook for HCC and How to Choose Treatments
June 10th 2024Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.
Read More
Health Equity and Access Weekly Roundup: June 8, 2024
June 8th 2024This week, the Center on Health Equity and Access covered the release of the best US hospitals for equitable access, news from the CMS Health Equity conference, biomarker testing legislation, and insights on improving access for queer communities and the disparities in dermatology.
Read More
CHESS II: Hemophilia Severity Correlates With Economic Burden, Patient QOL
June 7th 2024The data come from the observational Cost of Hemophilia in Europe: A Socioeconomic Survey II (CHESS II) study of 288 Spanish patients with hemophilia A and B, which showed certain differences between disease subtypes but overall similar trends in disease impact.
Read More
Experts Share Health Equity Advances in Value-Based Care at CMS Conference
June 7th 2024During the CMS Health Equity conference, the “Implementing Health Equity Through Value-Based Care for People in Medicare” session featured a series of expert speakers who shared insights on pioneering strategies designed to advance health equity.
Read More
Dr Christopher Flowers: Liso-Cel Approval for Mantle Cell Lymphoma Changes the Treatment Strategy
June 7th 2024The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher Flowers, MD, of MD Anderson Cancer Center.
Read More
Inotuzumab Ozogamicin Plus Dose-Adjusted EPOCH: Promise in R/R B-ALL
June 5th 2024Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).
Read More
Prophylaxis With Recombinant ADAMTS13 Demonstrates Superiority vs Standard Therapy in Congenital TTP
June 5th 2024The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients with congenital thrombotic thrombocytopenic purpura (cTTP) compared with standard therapy.
Read More